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The knowledge and understanding of all aspects of liver cancer
[this including hepatocellular carcinoma (HCC) and intrahepatic
cholangiocarcinoma (iCCA)] have experienced a major improve-
ment in the last decades. New laboratory technologies have iden-
tiﬁed several molecular abnormalities that, at the very end,
should provide an accurate stratiﬁcation and optimal treatment
of patients diagnosed with liver cancer. The seminal discovery
of the TP53 hotspot mutation [1,2] was an initial landmark step
for the future classiﬁcation and treatment decision using conven-
tional clinical criteria blended with molecular data. At the same
time, the development of ultrasound, computed tomography
(CT) and magnetic resonance (MR) has been instrumental for ear-
lier diagnosis, accurate staging and treatment advances. Several
treatment options with proven survival beneﬁt if properly
applied are now available. Major highlights include: i) acceptance
of liver transplantation for HCC if within the Milan criteria [3], ii)
recognition of ablation as a potentially curative option [4,5], iii)
proof of beneﬁt of chemoembolization (TACE), [6] and iv) incor-
poration of sorafenib as an effective systemic therapy [7]. These
options are part of the widely endorsed BCLC staging and treat-
ment model (Fig. 1) [8,9]. This is clinically useful and it will
certainly keep evolving to accommodate new scientiﬁc evidence.
This review summarises the data which are the basis for the
current recommendations for clinical practice, while simultane-
ously exposes the areas where more research is needed to fulﬁl
the still unmet needs (Table 1).
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V.
Epidemiology
Liver cancer (including HCC and iCCA) is the 2nd cause of cancer
related death [10] and one of the cancers with a still increasing
incidence rate [11]. Since risk factors are well known, prevention
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E-mail address: jbruix@clinic.ub.es (J. Bruix).is an achievable aim. Control of hepatitis B (HBV) and C (HCV)
infection, as well as reduction in alcohol consumption would
have a huge impact if applied on a large scale. While health plans
are implemented to achieve this goal, the epidemic of overweight
and metabolic syndrome has emerged as a relevant risk factor
[12]. Prospective follow-up data about incidence and speciﬁc
high-risk individuals in this subset as compared to HBV, HCV or
alcohol are still scarce. However, the future reduction in viral
related cases because of HBV and HCV control is counterbalanced
by the increase in such an etiologic group.
Cancer related death will decrease due to a reduction in expo-
sure to risk factors and because of a higher rate of early diagnosis
leading to effective treatment with long term disease free sur-
vival. This is the basis to recommend screening for HCC in the
population at risk [4,5]. Some restrictions should be in place to
make screening cost-effective [13]. Risk should be high enough
and modelling studies have placed such cut-offs at an annual rate
of 1.5% [14]. Such a ﬁgure is exceeded in liver cirrhosis of most
etiologies [15,16]. In addition, patients entering screening should
be suitable for treatment if they would be diagnosed with HCC. If
comorbidities or end-stage liver disease not leading to transplant
exist, screening and diagnosis of HCC and its potential treatment
will be of no beneﬁt. Finally, diagnosis, accurate and effective
options should be available. Unfortunately, an unknown propor-
tion of patients with cirrhosis may not be yet diagnosed, and even
so, implementation of screening is usually suboptimal. In the
future, the evaluation of the speciﬁc risk in an individual patient
and prognostic prediction will be reﬁned by molecular proﬁling
of the oncogenic cirrhotic liver and the tumor.Molecular pathogenesis and signalling pathways
Molecular classiﬁcation should aid in understanding the biologi-
cal subclasses and drivers of cancer and optimize beneﬁts from
molecular therapies and enrich trial populations [5]. From the
biological standpoint, different HCC classes have been character-
ized including a Wnt subclass (25% of cases; enriched with
CTNNB1 mutations and HCV etiology), a proliferation class (with
two subclasses: S1-TGF-beta and S2-EpCAM positive) and an
inﬂammation/interferon class [17–20]. The proliferation subclass
accounts for 50% of cases and is enriched with tumors derived
from progenitor cells (e.g., ‘‘EpCAM’’2) and tends to have worse15 vol. 62 j S144–S156
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Fig. 1. BCLC staging and treatment strategy [as per Semin Liver Dis. 2014 Nov;34(4):444–55]. The ﬁgure represents the ﬁrst approach to the evaluation of the patients
with expected prognosis and initial treatment option to be considered. As shown, the upper part of the scheme deﬁnes prognosis according to the relevant clinical and
tumor related parameters. Bottom part depicts the decision process to select a treatment option for ﬁrst consideration. As in all recommendations, ﬁnal treatment
indication should take into account a detailed evaluation of additional characteristics (age, comorbidities) of the patients that imply a personalized decision making. ⁄Note
that Child-Pugh classiﬁcation is not sensitive to accurately identify those patients with advanced liver failure that would deserve liver transplant consideration. Some
patients ﬁtting into Child-Pugh B, and even A, may present a poor prognosis because of clinical events not captured by such system, i.e. spontaneous bacterial peritonitis,
recurrent variceal bleeding, refractory ascites with or without hepatorenal syndrome, recurrent encephalopathy, severe malnutrition. ⁄⁄Patients with end-stage cirrhosis
due to heavily impaired liver function (Child-Pugh C or earlier stages with predictors of poor prognosis, high MELD score) should be considered for liver transplantation. In
them, HCC may become a contraindication if exceeding the enlistment criteria.
JOURNAL OF HEPATOLOGYprognosis. Nonetheless, no molecular subclass has been reported
to respond to speciﬁc targeted therapy [5].
Several prognostic mRNA-based molecular signatures from
tumor or non-tumoral adjacent tissue have been reported
[21,22]. Signatures identifying progenitor cell-like and/or a
cholangiocyte proﬁle (EPCAM signature3, CK19 signature [22])
display worse prognosis. Similarly, a 5-gene score signature
(TAF9, RAN, RAMP3, KRT19, and HN1 genes) predicted overall sur-
vival in four independent cohorts of Caucasian and Asian patients
[23]. In parallel, gene expression proﬁling of adjacent non-tu-
moral liver tissue has highlighted the importance of tumor
microenvironment in HCC prognosis. The poor prognosis with
186-gene signature was associated with both survival after resec-
tion and survival, HCC occurrence and decompensation in cir-
rhotic HCV patients without tumors [24,25]. Molecular proﬁling
together with assessment or major clinical predictors of risk of
HCC and death (degree of portal hypertension, concomitant treat-
ments during follow-up, sustained alcohol intake or coffee con-
sumption) and comorbidities will permit a more personalised
approach.Journal of Hepatology 2015Oncogenic drivers and tumor suppressors
High-resolution analysis ofmolecular alterations in humanmalig-
nancies has allowed for the identiﬁcation of new drivers, which
are ideal targets for treatments in some solid malignancies (lung,
breast or melanoma). Recent studies have provided a broad
picture of the mutational proﬁle in HCC and identiﬁed an average
of 30–40 mutations per tumor, among which 6–8 are considered
drivers [26,27]. Main mutations are in the promoter region of
TERT, TP53, CTNNB1, ARIDA1A, and Axin 1 (Table 2). Deep-sequenc-
ing studies conﬁrmed TP53 and CTNNB1 are frequently mutated.
Mutations in these genes are mutually exclusive – an indication
that they could act as drivers of tumor progression. In addition,
these studies discovered novel mutations in genes involved in
the chromatin remodelling pathway (ARID1A and ARID2), in ubiq-
uitination (KEAP1), RAS/MAPK signalling (RPS6KA3) and oxidative
stress (NFE2L2) and JAK1 in 9% of HBV-related HCC. Genes com-
monly mutated in other solid tumors such as EGFR, PIK3CA or
KRAS are rarely mutated in HCC (<5% of cases, Table 2 [26,27]).
Several chromosomal alterations have been recurrently identiﬁed.vol. 62 j S144–S156 S145
Table 1. Major unmet needs in the ﬁeld of HCC.
1. Detection of the population at risk for HCC in the community in order to recruit them into early HCC detection plans.
2. Stratification of the risk for HCC to distinguish those at significant risk from those with minimal or no risk (blending conventional 
clinical assessment and molecular profile).
3. Development of biomarkers to detect liver cancer development prior to image recognition. 
4. Development of minimally invasive imaging techniques to detect and characterise liver nodules prior to their over malignant 
transformation.
5. Validation of organ specific contrasts for accurate diagnosis of nodules detected during screening.
6. Development and prospective validation of a molecular classification of liver cancer that would allow refined prognosis prediction 
and optimised treatment selection. 
7. Identification and prospective validation of biomarkers to recognise therapeutic targets that would indicate the benefit of a specific 
systemic treatment.
8. Development of functional imaging criteria for the recognition of response and treatment failure in systemic therapy.
9. Development and validation of HCC specific criteria for the definition of objective response and disease progression that would 
reliably predict significant therapeutic activity and survival benefit.
10. Design of randomised trials to evaluate adjuvant options after curative treatment, combined/sequential treatment approaches and 
novel therapeutic options.
11. Elucidate the molecular nature of mixed hepato-cholangio tumors and their specific prognosis and treatment approach.
Table 2. Landscape of the most prevalent mutations and high-level gene ampliﬁcations in human HCC (modiﬁed from Llovet et al., Cancer Cell 2014;22).
Gene Pathways/gene functions involved Estimated frequency based on deep-sequencing studies (%)
Driver genes frequently mutated in HCC
TERT promoter Telomere stability 60
TP53 Genome integrity 20-30
CTNNB1 WNT signalling 15-25
ARID1A, ARID2 Chromatin remodelling 10-16
TTN Chromosome segregation 4-10
NFE2L2 Oxidative stress 6-10
JAK1 JAK/STAT signalling 0-9
Oncogenes/tumor suppressors rarely mutated in HCC
IDH1, IDH2 NAPDH metabolism <5
EGFR Growth factor signalling <5
KRAS, NRAS RAS/MAPK signalling <5
PIK3CA AKT signalling <5
PTEN AKT signalling <5
Oncogenes contained in high-level amplifications in HCC
FGF19 FGF signalling 5-10
CCND1 Cell cycle 5-10
VEGFA HGF signalling/angiogenesis                                   7-10
ReviewThese include; (i) high level ampliﬁcations at 5–10% prevalence
containing oncogenes in 11q13 (Cyclin D1 and FGF19) and 6p21
(VEGFA)2, TERT focal ampliﬁcation [28] and homozygous deletion
of CDKN2A; [28] and (ii) common ampliﬁcations containing Myc
(8q gain) and Met genes (focal gains 7q31). No oncogenic addic-
tion loop for any driver has been deﬁned in HCC.S146 Journal of Hepatology 2015Signalling pathways
Hepatocarcinogenesis is a complex multistep process where mul-
tiple signalling cascades are altered. This leads to a heteroge-
neous biological portrait. Several signalling pathways are
implicated:vol. 62 j S144–S156
Table 3. Molecular abnormalities and potential therapeutic agents.
Altered pathway/function Genes involved Somatic mutations 
(reported mutations)
Targeted therapy
Telomere stability TERT promoter ~60% Vx-001 (immunotherapy) 
BIBR1532 (telomerase inhibitor) 
GRN163L (antisense nucleotides) telomelysin (gene therapy)
TERT 11%
TP53/cell cycle control TP53 20-30% Adenovirus p53 construct (gene therapy, phase I)
RG7112 (inhibition of p53-MDM2 interaction, phase I)
c-myc
CDKN2A 7-10% 
ATM 4-5%
RB1 3-10%
IRF2 1-5%
CCND1
CCNE1 4-5% 
CDKN1A 1-4% 
Wnt/β-catenin signaling CTNNB1 9-41%
AXIN1 4-15%
APC 2-3%
Chromatin remodeling ARID1A 10-17% 
ARID1B 2-7%
HDAC family 
members
Resminostat, vorinostat, belinostat (pan-HDAC inhibitors)
ARID2 5-9% 
MLL3 4-13%
MLL 1-6%
MLL2 1-6% 
PI3K/Akt/mTOR pathway RPS6KA3 2-10% Everolimus, termsirolimus, (mTOR inhibitor)
PIK3CA <5%
PTEN 4-5%
JAK/STAT signaling JAK1 0-9% Baricitinib and AZD1480 (JAK inhibitors) 
VEGF signaling VEGFA Bevacizumab (monoclonal antibody against VEGFA)
Ramucirumab (monoclonal antibody against VEGFR2, a VEGFA receptor)
Cabozantinib (dual VEGFA/c-MET TKI)
Brivanib (VEGFR2 and FGFR TKI)
Sorafenib, regorafenib, sunitinib, linifanib, lenvantinib, axitinib (multi TKIs)
FGF signaling FGF19 BGJ398 (pan FGFR inhibitors) 
FGFR4 inhibitors
Brivanib (VEGFR2 and FGFR TKI)
FGFR4 1%
FGFR2 1%
FGF5 1%
IGF signaling IGF2R MEDI-573 (monoclonal antibody against IGF1/IGF2)
Cixutumumab, BIIB022, dalotuzumab (monoclonal antibodies anti-IGF1R)IGF1R
RAS/RAF/MEK/ERK pathway KRAS/NRAS 2% Sorafenib (multi TKIs) 
Vemurafenib (BRAF inhibitor)BRAF <5%
MET signaling c-MET Selumetinib (MEK/ERK inhibitor) 
Refametinib (MEK inhibitor)
Sorafenib (multi TKIs) 
Cabozantinib (dual VEGFA/c-MET TKI)
Tivantinib (c-Met inhibitor)
PDG signaling PDGFRA 2% Sorafenib, regorafenib, linifanib, orantinib, sunitinib (multi TKIs)
EGF signaling EGFR <5% Cetuximab (monoclonal antibody against EGFR)
Erlotinib and gefitinib (EGFR TKIs)
Proteasome system UBE3C 1-16% Bortezomib (proteasome inhibitor)
JOURNAL OF HEPATOLOGY1) Vascular endothelial growth factor (VEGF) signalling is
the cornerstone of angiogenesis in HCC. High level
ampliﬁcations have been identiﬁed in 7–10% of cases
[17,29]. VEGFR signalling can be targeted by the
monoclonal antibody bevacizumab directed against
VEGF-A ligand or by ramucirumab targeting theJournal of Hepatology 2015VEGFR-2, or by inhibiting the intracellular tyrosine
kinase by small molecules such as sorafenib. Other acti-
vated angiogenic pathways are Ang2 and FGF signalling.
In a retrospective analysis, VEGFA ampliﬁed tumors
have been suggested to be more responsive to sorafenib
[29].vol. 62 j S144–S156 S147
Table 4. Diagnostic criteria for HCC.
• Tumor biopsy
• Imaging criteria (only for patients at high risk for HCC
(EASL, AASLD): recognition of a nodule >10 mm with
increased contrast uptake (“washin”) followed by reduced
contrast uptake (“washout) in venous/delayed phases at
dynamic imaging at CT or MR (AASLD, EASL, LIRADS)
• Organ specific contrast have not been validated for diagnosis
• AFP and other tumor markers are not recommended to set
HCC diagnosis.
Review
2) Ras MAPK signalling is activated in half of early and almost
all advanced HCCs [30,31]. Activation results from up-
stream signalling by EGF, IGF, and MET activation, and
from the epigenetic silencing of tumor suppressors such
as NORE1A, and RASSF1A15. Mutations of K-Ras are infre-
quent (<5%). Sorafenib and regorafenib have shown partial
cascade blockage.
3) The PI3K/PTEN/Akt/mTOR pathway controls cell prolif-
eration, cell cycle and apoptosis, and is activated by var-
ious RTKs such as EGFR or IGFR and inactivated by PTEN
[32,33]. It is activated in 40–50% of HCCs [32].
4) Dysregulation of the c-MET receptor and its ligand HGF,
critical for hepatocyte regeneration after liver injury, are
common events [18,30]. MET activation occurs in 50% of
advanced HCC, but activating mutations or ampliﬁcations
represent less than 5% of cases [34].
5) Insulin-like growth factor receptor (IGFR) signalling is acti-
vated in 20% of cases through; a) allelic loss affecting the
tumor suppressor IGF2R; b) overexpression of the onco-
genic ligand IGF2; and c) deregulation of the IGF binding
proteins IGFBP2 and IGFBP3 [35].
6) Wnt/b-Catenin pathway is crucial for hepatocarcino-
genesis [36,37]. Around half of HCCs have activation of
the Wnt signalling pathway, either as a result of b-catenin
mutation, or overexpression of Frizzled receptors or inacti-
vation of E-cadherin [36,37].
Additional pathways and their role in targeted therapy such as
the extrinsic/intrinsic apoptotic pathway, Hedgehog signalling,
JAK/STAT signalling, TGF-b signalling, Notch pathway,
Ubiquitinin-Proteasome pathway, nuclear factor-jB signalling,
EGFR signalling, cell cycle control, and the role of the tumor
microenvironment have to be further deﬁned (Table 3).
Similarly, the potential role of recently described oncoMIRs rele-
vant to hepatocarcinogenesis as molecular targets should be con-
ﬁrmed by clinical investigations.Screening, diagnosis and staging
Screening for HCC in the population at risk should be based in
ultrasound examination every 6 months [4,5,38]. Adding tumor
marker determination provides no beneﬁt. Alpha-fetoprotein
(AFP) is a predictor of advanced disease and poor prognosis.
Hence, even if some cases could be detected through AFP, these
would not likely belong to early stage [39,40].
The goal of screening is to detect solitary tumors 620 mm,
when the likelihood of vascular invasion or intrahepatic spread
is low and curative treatment is highly likely [41]. Nodules
<10 mm within a cirrhotic liver are frequently not malignant
and accurate diagnosis is extremely challenging by biopsy or
imaging techniques. Thus, active diagnostic approach is initiated
when nodule size exceeds 10 mm (Table 4). If such a nodule pre-
sents increased contrast uptake in the arterial phase, followed by
contrast washout in the venous/delayed phases of dynamic imag-
ing (CT, MR) the diagnosis is established without need of biopsy
conﬁrmation [5,38,42–44]. Organ speciﬁc contrasts await proper
evaluation and their routine use is not currently endorsed
(Table 4) [43]. If the pattern is not this speciﬁc one, diagnosis
should be based from biopsy, that is mandatory to diagnose
iCCA [39]. AFP is again of limited use as it may increase both inS148 Journal of Hepatology 2015HCC and in iCCA [4], and positron emission tomography (PET)
has no value for diagnosis.
Evaluation of the patients to estimate prognosis should take
into account tumor burden, liver function and general health sta-
tus. Presence of cancer related symptoms (assessed through the
performance status test or the Karnofsky index [45]) is associated
to poor outcome. Evaluation of liver function should not simply
be based on Child-Pugh as this does not allow proper stratiﬁca-
tion. Parameters such as episodes of encephalopathy, renal fail-
ure, bacterial peritonitis, hyponatremia and others indicate end-
stage liver disease in need of transplant evaluation irrespective
of Child-Pugh A or B class [46,47]. MELD has also limited dis-
crimination capacity if liver function is not at end-stage [48].
Indeed, if liver function would prime liver transplant evaluation
in the absence of HCC, the presence of HCC may just become a
contraindication for it and thus, such patients should be classiﬁed
as end-stage [9,49].Resection, transplantation and ablation: Signs of progress in
the never ending debate
Years ago the competition between resection, transplantation
and ablation was fuelled by the absence of robust data. Now,
we have a large set of informative studies about the beneﬁts of
each option and its long term results in survival. It needs to be
stressed that the endpoint of treatment is to provide the longest
survival with the less impaired quality of life. Thereby, goals of
tumor removal or lower recurrence risk if survival is not modiﬁed
should not be the driver to favor one option. As a consequence,
the debate should take into account the outcome that each option
is able to provide in different proﬁles of patients as per tumor
burden and liver function [50].
If patients present hepatic decompensation, the expected out-
come offered by liver transplantation, if the Milan criteria are not
exceeded, is clearly superior to surgery and ablation. Indeed, sur-
gical resection should be considered contraindicated in such
instance, and even ablation may not have a positive impact, as
the impaired liver function already determines a dismal outcome.
Accordingly, the debate affects patients with compensated liver
disease and among them, those with solitary HCC smaller than
2 cm or up to 3 cm at most. Survival of multifocal HCC within
Milan criteria is still optimal (>70% at 5 years) after transplant,
while resection and ablation may initially be effective, but HCC
recurrence will reduce long term survival (50% at 4–5 years). In
that proﬁle, TACE could become a competitive option as proper
selection and technique may provide similar survival [51–54].
Prospective trials with adequate sample size and design are need-
ed to deliver an evidence-based recommendation.vol. 62 j S144–S156
AB
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Large tumors are not well served by ablation. Long lasting
complete response in HCC >3 cm is less frequent and recurrence
rate is high [55]. Contrarily, resection may be successful and this
is why tumor size does not constitute a contraindication by itself
[5,8,42]. Increased size parallels risk of vascular invasion and dis-
semination as reﬂected by satellites or additional nodules
[56,57]. However, some patients may develop expansive tumors
and not suffer dissemination. If liver function is preserved resec-
tion may provide optimal results. Tumors larger than 5 cm are
not within the recommended transplant criteria, but this is due
to the lack of enough donors. If the availability of organs would
be unlimited, the selection criteria would be surely expanded.
New criteria may take into account parameters such as AFP, total
tumor burden/volume and/or response to treatment even if base-
line stage would be beyond the criteria [58–62]. Prospective
research needs to be ﬁnished in order to validate all approaches
[63]. Indeed, because of the shortage of donors, there is a delay
between transplant indication and the procedure. During this
time, HCC may progress and prime exclusion from the list.
Priority policies are applied in most transplant programs. They
may leave solitary tumors <2–3 cm without priority and hence,
no real chance of transplantation unless liver failure primes it.
Thus, only large and/or progressing HCC get priority. Since this
proﬁle is associated to a more advanced disease, priority may
bring a reduction in post transplant outcomes. The risk of incon-
sistencies in liver graft allocation for HCC may be limited by ben-
eﬁt consideration, intended as the difference in outcome with or
without transplant when alternative treatments are applicable
[64,65]. Several attempts of allocation on the net beneﬁt in sur-
vival are likely to be developed, as the utility of transplant on
the sole basis of absolute survival may not serve equally the large
population of end-stage liver diseases without cancer (Table 5).
In patients without hepatic decompensation the survival after
resection and ablation is inﬂuenced by the existence of clinically
signiﬁcant portal hypertension [66–68]. In the absence of portal
hypertension the 5-year survival exceeds 70% and when it is pre-
sent it is signiﬁcantly reduced. If survival for very early HCC isTable 5. The conﬂict between urgency, utility and beneﬁt when developing
priority policies in patients considered for liver transplantation (adapted from
Bruix et al. Gut 2014:1–12).
Model Definition
Urgency Focused on pre-transplant risk of dying: patients with 
worse outcome on the waiting list are given higher 
priority for transplantation (based on Child-Pugh 
or MELD score)
Utility Based on maximization of post-transplant outcome. 
Takes into account donor and recipient characteristics: 
mainly used for HCC since the MELD score poorly 
predicts post-transplant outcome in HCC, due to 
the absence of donor factors and lack of predicting 
progression while waiting
Benefit Calculated by subtracting to the survival achieved 
with LT the survival obtained without LT. The benefit 
approach ranks patients according to the net survival 
benefit that they would derive from transplantation and 
maximize the lifetime gained through transplantation. 
If applied to HCC without adjustments may prioritize 
patients at highest risk of progression, higher 
recurrence rate and lower survival
Journal of Hepatology 2015similar for resection and ablation, what are the beneﬁts of resec-
tion? In large tumors, a safety margin may beneﬁt, but this is also
highly debated. In HCC <3 cm both ablation and resection may
provide a safety margin, but in HCC <2 cm the risk of satellites
is low and margin beneﬁt may not exist. Resection allows pathol-
ogy inspection. If microvascular invasion or satellites are detect-
ed, the risk of recurrence is high [69]. Some authors propose
enlistment because of risk (priority based in imaging prior to sur-
gery) [70,71]. This may be a relevant beneﬁt from surgery. Finally,
tumor location and need of extensive liver resection are also
involved in treatment selection (Fig. 2). All these variables con-
found the picture and explain why trials in this setting are chal-
lenging and likely will never be strong enough to inform a robust
decision in individual patients [72].Fig. 2. Personalised decision making in a patient with HCC. (A) Macroscopic
view of a resected HCC in a patient with cirrhosis due to HCV infection. Diagnosis
was based on imaging techniques and its size was between 3 and 4 cm. Liver
function was preserved, but there was clinically signiﬁcant portal hypertension
(hepatic venous pressure gradient = 11 mmHg). Liver transplant was contraindi-
cated because of comorbidities and its location protruding in the liver surface
precluded safe ablation (direct access without a protective rim of non-tumoral
liver is associated to increased risk of bleeding and peritoneal seeding). In
addition, size >30 mm is a predictor of incomplete ablation. Because of these
considerations it was decided to recommend surgical resection through
laparoscopy. (B) Partition of the HCC shows capsule formation and no macro-
scopic satellites. It is possible to differentiate the separate tumor areas and even
some minute intratumoral nodules. There is a necrotic haemorrhagic area in the
central part. This macroscopic heterogeneity (also identiﬁed by different differ-
entiation degrees across the nodule) predicts a heterogeneous molecular proﬁle if
assessed by any of the currently available technologies. Increased proliferation
markers will be present everywhere, but tumor needle biopsy will be at risk to fail
to accurately inform about the tumor biology proﬁle.
vol. 62 j S144–S156 S149
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The availability of effective treatments for HCV infection will
have an impact in the future. The number of patients reaching
end-stage cirrhosis in need of transplant may decrease and the
problems related to reinfection of the graft will be controlled.
Thereby, the demand of organs for end-stage cirrhosis may
decrease and allow an expansion of the criteria for HCC patients.
Furthermore, if HCV is cured, the risk of recurrence due to de novo
tumors in the cirrhotic liver may no longer be a major concern
after a ﬁrst resection/ablation. The data of the potential impact
of HCV eradication with prior treatments [73] and in HBV
patients treated with antivirals reinforce this hope and suggest
that in the future the advantage of transplant to prevent onco-
genic risk may not be a valid concept. Only recurrence due to dis-
semination will still be a major problem. All trials using different
agents to reduce recurrence risk have failed [74]. This is an area
where active research is needed.Locoregional approach
Locoregional treatments are widely used in intermediate-stage
HCC. They include ablation, conventional TACE (cTACE), TACE
with drug-eluting beads (DEB-TACE), transarterial radioem-
bolization (TARE), hepatic arterial infusion chemotherapy
(HAIC) and external radiotherapy.
The role of ablation as compared to surgery has been dis-
cussed above. Radiofrequency (RFA) is the ﬁrst line technique,
but its failure rate increases in HCC >3 cm [75,76]. Microwave
ablation is a promising option that may successfully ablate larger
tumors, but long term data are needed. Same applies to high
intensity focused ultrasound.
To overcome the current limitations, several approaches have
been investigated. Intravenous administration of ThermoDox, a
heat-activated formulation of liposomal doxorubicin, delivers
higher concentrations of anti-cancer drugs directly to the periph-
ery of RFA ablation zone, which are most commonly responsible
for post-treatment tumor recurrence [77]. Unfortunately, a phase
III trial comparing ThermoDox plus RFA with RFA alone has
been negative [78]. Combination of RFA with TACE has also been
evaluated, but despite suggestions of improved efﬁcacy, robust
evidence is lacking in patients beyond the optimal proﬁle for
RFA [78–80].
Transarterial treatment was initiated in the 1970s. First
approach was simply bland embolization aiming to obstruct the
arterial blood ﬂow [81,82]. Studies combining selective arterial
obstruction with anti-cancer drug injection (TACE) showed that
TACE improves survival of patients with HCC [6,83,84].
Cumulative meta-analysis comparing its efﬁcacy against support-
ive care has placed TACE as the 1st line treatment option for
patients with BCLC intermediate-stage HCC [6]. However, there
is still no standardized protocol for TACE in terms of treatment
schedule, type and dosage of anti-cancer drug. Moreover, the
uneven size of embolic material when using gelatin sponge is
another limiting factor to predict its therapeutic efﬁcacy [85].
TACE is associated with transient post-embolization syndrome
in most cases, but severe events such as hepatic decompensation,
gastrointestinal bleeding and abscess are infrequent [86].
The use of spheres that slowly release chemotherapy while
also obstructing arterial blood supply (DEB-TACE) has improved
tolerance and enabled standardization. DEB-TACE uses
anthracycline-loaded beads rather than the conventionalS150 Journal of Hepatology 2015lipiodol-anthracycline emulsion [87,88]. The sustained release of
anti-cancer drugs primes a lower systemic drug exposure with
higher drug concentration within the tumor. As a result, while
maintaining treatment efﬁcacy the systemic adverse events due
to chemotherapy are reduced [86,88]. The most relevant issue in
TACE is to follow the recommendations in guidelines about when
to start and when to interrupt. TACE is effective in HCC patients
with compensated liver disease and without cancer related
symptoms, vascular invasion or extrahepatic spread. TACE
should induce major necrosis and may be repeated upon disease
progression. However, if TACE fails to induce response or the
criteria to start are no longer present at the time of progression
(liver failure, symptomatic disease, vascular invasion/spread)
TACE should not be repeated. Applying the recommendations
the median survival of TACE treated patients should exceed
3 years. Lower ﬁgures indicate inadequate selection or suboptimal
treatment application.
The hypoxic tumor microenvironment resulting from arterial
embolization induces release of pro-angiogenic factors, such as
VEGF and platelet-derived growth factor (PDGF), which adversely
affect the prognosis of patients. This provides the rationale to
combine TACE with sorafenib, since sorafenib inhibits the action
of pro-angiogenic factors [89]. While the combination is safe, data
from phase II studies have not shown a clinically signiﬁcant ben-
eﬁt. Thus, adjuvant treatments to TACE are still needed [90,91].
TARE has shown signiﬁcant activity. Its application requires a
complex setting and this may limit its widespread use. TARE acts
by delivery of glass or resin spheres loaded with a radiation agent
such as Yttrium-90 or Holmim-166 that are pure b-emitters
[92,93]. TARE has less severe short term adverse events compared
to TACE [94]. However, actinic damage may appear months after
treatment and this demands a careful evaluation of the amount of
radiation required to treat the tumor and gauge the risk associat-
ed with large, multifocal HCC affecting both lobes. Several hetero-
geneous study populations show survival rates similar to TACE
and sorafenib, particularly in patients with advanced-stage HCC
with portal vein thrombosis [95,96]. Ongoing randomized con-
trolled trials comparing TARE with TACE or sorafenib should
deﬁne its value.
HAIC consists of the selective infusion of chemotherapy into
the tumor-feeding hepatic artery through a chemoport. It pro-
vides localized delivery of a high dose of anti-cancer drugs,
expecting that the ﬁrst-pass effect in the liver, would reduce sys-
temic concentration and prevent drug related adverse effects.
There is no standardized protocol for HAIC, and despite its wide
use in some settings, there is no proof of survival beneﬁt [97–99].
Focal high-dose external radiation therapy, including stereo-
tactic body radiation therapy, can be used to treat locally
advanced HCC with or without portal vein thrombosis
[100,101]. Better tumor targeting may avoid actinic damage of
the non-tumoral liver and surrounding structures. It may be used
alone or in combination with other treatments, but in the absence
of prospective randomised trials assessing its value, no robust rec-
ommendation is feasible. Selective radiation of early stage HCC
may be a niche competing with percutaneous options [102,103].Systemic treatment
Absence of proven survival beneﬁt has been the rule in the eval-
uation of a large number of systemic agents [8]. Conventionalvol. 62 j S144–S156
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chemotherapy, either alone or in combination, administered
intravenously or intra-arterially, or following different regimes,
never reached positive results [8]. The last failure affected the tri-
al comparing FOLFOX4 (ﬂuorouracil, leucovorin, and oxaliplatin)
vs. doxorubicin in an Asia based trial [103]. The primary analysis
of the study showed no difference in survival and the suggestion
of a positive outcome based in an extended follow-up period does
not have scientiﬁc strength. Indeed, it could be argued that the
use of doxorubicin in the control arm in a population with high
HBV carriage may have impaired their survival. Therapies such
as antiestrogens, antiandrogens, vitamin D derivatives or inter-
feron have also failed to offer any beneﬁt [8].
This dismal status changed with the success of sorafenib [7].
This agent is part of a large group of novel agents that target
speciﬁc molecular mechanisms related to cancer development
and progression. Because of the hypervascular nature of HCC, a
major activity has been focused on angiogenesis pathways but
several other targets have been identiﬁed and tested (Table 2).
Unfortunately, none has beaten the beneﬁts of sorafenib
(Table 6), a multi-kinase inhibitor that reduces tumor-cell prolif-
eration and tumour angiogenesis. It acts by inhibiting the serine-
threonine kinases Raf-1 and B-Raf and the receptor tyrosine
kinase activity of VEGF receptors (VEGFRs 1-3) and PDGF, among
others. Despite the absence of a signiﬁcant response rate accord-
ing to conventional RECIST criteria, it was envisioned that the
efﬁcacy could come from a delay in tumor progression that
would ultimately translate into improved survival. This was
demonstrated in the pivotal trial testing sorafenib vs. placebo
[7], and the simultaneous trial run in the Asia-paciﬁc region
[104]. In both instances the survival expectancy was improved
by 30% after a signiﬁcant delay in tumor progression. Again, it
was shown that the response rate according to conventional cri-
teria was marginal, thus dismissing this parameter as a valuable
tool to unequivocally detect therapeutic activity of novel agents.
The survival beneﬁt at advanced stages is still modest and
hope was placed in the potential efﬁcacy of other therapeutic
agents with similar proﬁles, but with heterogeneous potency
against speciﬁc targets, and also agents affecting other pathways.
Unfortunately, none of those tested so far has offered survival
beneﬁt. Table 4 displays the results of the seminal sorafenib trials
and those obtained with sunitinib [105], brivanib [106], linifanib
[108] and the combination of sorafenib with erlotinib [109] in
ﬁrst line vs. sorafenib, as well as the data in second line testing
brivanib [110], everolimus [111] and ramucirumab [112]Table 6. Randomized phase III clinical trials completed in HCC in ﬁrst and second
2014;28(5):921–35).
Drug in study Author Year Randomized drugs
Sorafenib Llovet et al., [7] 2008 Sorafenib vs. placebo
Cheng et al., [104] 2009
Sorafenib plus 
erlotinib
Zhu et al., [108] 2012 Sorafenib + erlotinib vs.
sorafenib
Linifanib Cainap et al., [107] 2012 Linifanib vs. sorafenib
Sunitinib Cheng et al., [105] 2013 Sunitinib vs. sorafenib
Brivanib Johnson et al., [106] 2013 Brivanib vs. sorafenib
FOLFOX-4 Qin et al., [103] 2013 FOLFOX-4 vs. doxorrub
Brivanib Llovet et al., [109] 2013 Brivanib vs. placebo
Everolimus Zhu et al., [110] 2014 Everolimus vs. placebo
Ramicirumab Zhu et al. [111] 2014 Ramicirumab vs. placeb
n.s., not signiﬁcant; TTP, time to progression; OS, overall survival.
Journal of Hepatology 2015(Table 6). While these failures are disappointing, dissection of
their results have provided meaningful insight to elaborate
around the reasons for such negative outcomes. The ﬁrst argu-
ment may be that the drugs are not effective enough for all com-
ers or that their effectiveness is counterbalanced by the lack of
safety that would turn into treatment related death, such might
be the case of sunitinib [106]. The second argument would affect
the design of the trials. The deﬁnition of the target population is
key to have an informative trial and the characterization of the
patient stage and their prognostic predictors may have changed
in recent years. The evolution of the path of care of patients with
liver cancer has primed an earlier diagnosis with indication of
locoregional and systemic treatment at a less advanced stage in
which the prognostic predictors have to be reﬁned. Pattern of
progression after treatment was already known to be a prognos-
tic predictor after resection, ablation and TACE, and it has now
been shown to be relevant under sorafenib treatment [113].
Thus, trial design should not only consider the usual parameters
(tumor burden, liver function), but also progression pattern.
Speciﬁc adverse events related to sorafenib intake (i.e. derma-
tology reactions) are associated to a slower time to progression
and improved survival [114]. Hence, trials in second line should
also consider this clinical event to avoid a further risk of bias.
Finally, if targeted therapy is aimed to act on speciﬁc targets it
would make sense to select patients according to the recognition
of the molecular pathway to be modulated. This enrichment pol-
icy is sound but the challenge is how to properly proﬁle the
biomarker status. HCCs present a marked heterogeneity within
the same nodule (Fig. 2) and across nodules making a single biop-
sy highly unlikely to provide an accurate proﬁling of the tumor as
per current technologies. In order to advance in knowledge it is
recommended that all therapeutic research trials should collect
tumor tissue to allow the investigation of the correlation between
the molecular proﬁle and the outcome of the patients. Research
in peripheral blood sampling (‘‘liquid biopsy’’) is the next techno-
logical challenge [115].
All these considerations have to be taken into account when
entering clinical evaluation of new drugs. Some of them share
in part the mechanisms of action of drugs previously tested but
with speciﬁc differences in potency and molecular targets.
Regorafenib, lenvatinib, cabozantinib and tivantinib are among
the currently being evaluated in phase III for regulatory approval.
The tivantinib trial is the only one enriched according to molecu-
lar proﬁle. The randomised phase II study testing tivantinibline (2007–2014) (Modiﬁed from Reig et al. Best Pract Res Clin Gastroenterol.
n TTP (mo) p value OS (mo) p value
299/303 5.5 vs. 2.8 <0.001 10.7 vs. 7.9 <0.001
150/76 2.8 vs. 1.4 <0.001 6.5 vs. 4.2 0.01
362/358 3.2 vs. 4 n.s. 9.5 vs. 8.5 n.s.
514/521 5.4 vs. 4 0.001 9.1 vs. 9.8 n.s.
530/544 3.6 vs. 3.6 n.s. 7.9 vs. 10.2 n.s.
577/578 4.2 vs. 4.1 n.s. 9.5 vs. 9.9 n.s.
icin 184/187 2.9 vs. 1.8 n.s. 6.4 vs. 4.9 n.s.
263/132 4.2 vs. 2.7 0.001 9.4 vs. 8.2 n.s.
362/184 2.9 vs. 2.6 n.s. 7.6 vs. 7.3 n.s.
o 283/282 3.5 vs. 2.6 <0.0001 9.2 vs. 7.6 n.s.
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showed that the therapeutic beneﬁt was observed only in
patients with c-met positivity by immunostaining and this pro-
vided the rationale for such design [116]. Others tackle mechan-
isms that are sharply different or complementary. These include
acting on methylation status or aiming to reactivate immune can-
cer surveillance [117], thus paralleling the success in melanoma.
Other studies are testing chemotherapy in combination with sor-
afenib or speciﬁc chemotherapy formulations to increase the
therapeutic activity. Results of all these efforts are eagerly
awaited.Intrahepatic cholangiocarcinoma (iCCA) and mixed HCC-iCCA
Liver cancers may contain features of both HCC and iCCA; these
malignancies are referred to as mixed HCC-iCCA using World
Health Organization (WHO) criteria [118]. In mixed tumors, the
presence of cholangiocarcinoma elements are often conﬁrmed
by positive cytokeratin 19 (CK19) staining. If one assumes that
CK19 positivity deﬁnes a mixed tumor, then its incidence is
approximately 11% [119]. The WHO criteria and many authors
have been reluctant to call CK19 positive HCC mixed tumors, pre-
ferring terms such as HCC with biliary/hepatic progenitor cell
markers [119]. However, one cannot infer cell lineage from mor-
phology, as transformed mature hepatocytes are plastic and may
assume a CCA phenotype [120]. Hence the deﬁnition of mixed
HCC-iCCA lesions likely will continue to evolve.
CCA accounts for approximately 15% of all hepatobiliary
malignancies [121]. Three anatomic subtypes of CCA can be
deﬁned including intrahepatic (iCCA), perihilar (pCCA), and distal
(dCCA) cholangiocarcinoma [121]. Although the overall incidence
of CCA has been increasing, the subtype of CCA responsible for
this increased incidence, intrahepatic vs. perihilar, has been
debated due to the frequent misclassiﬁcation of pCCA as iCCA.
However, at least one study has implicated an increase of iCCA
as responsible for this secular trend [122]. Although time-
honored risk factors for CCA have been identiﬁed, most cases
are sporadic and without known risk factors [121]. More relevant
to this review of HCC, there is a marked overlap between the risk
factors for HCC and iCCA including cirrhosis, chronic hepatitis B
and C, obesity, diabetes and alcohol [123]. Thus, in chronic
parenchymal liver disease the presence of a mass lesion cannot
be a priori diagnosed as HCC without a consideration of iCCA.
Molecular pathways
Awhole-exomesequencingof liver ﬂuke-relatedCCA tumors iden-
tiﬁed 206 somatic mutations in 187 genes [124]. Mutations were
identiﬁed in known cancer-associated genes including TP53,
KRAS, and SMAD4, and in newly implicated genes such as MLL3,
RNF43, PEG3, and ROBO2. These latter genes are involved in
deactivation of histonemodiﬁers, activationofG-proteins, and loss
of genomic stability [124]. A whole-exome sequencing study in
non-ﬂuke related CCA described inactivating mutations in multi-
ple chromatin-remodelling genes (including BAP1, ARID1A, and
PBRM1) [125]. Thus, the carcinogenesis process appears to be dif-
ferent depending upon etiology. A transcriptome proﬁling study
found not only KRASmutations as noted above, but also increased
levels of EGFR andHER2 signalling [126]. A single-nucleotide poly-
morphism array, gene expression proﬁle and mutation analysis of
iCCA specimens reported twosubsets of iCCA, an inﬂammation andS152 Journal of Hepatology 2015a proliferation class [20]. Oncogenic ROS1 fusions proteins have
also been reported in iCCA [127]. Thus, iCCA is also quite genetical-
ly diverse and heterogeneous.
Interestingly, isocitrate dehydrogenase 1 and 2 (IDH1 and
IDH2) mutations are found in approximately 20% of iCCA tumor
specimens [128]. Mutant IDH block liver progenitor cells from
undergoing hepatocyte differentiation in experimental models.
Combined IDH-KRAS mutations drive the expansion of liver pro-
genitor cells and induce progression to metastatic iCCA [129].
The epigenetic changes associated with these mutations likely
drive their oncogenic effects; IDH mutations may be amenable
to therapeutic targeting [130]. Another mutation common in
CCA are fusions of the FGFR gene [131–133], which can be target-
ed with current small molecule inhibitors such as BGJ398 or
ponatinib [134].
Staging of iCCA
Biopsy sets diagnosis and CT/MRI deﬁne tumor burden. Mass
forming iCCA as small as 1 cm may be detected by
ﬂuorodeoxyglucose PET (FDG-PET), but iCCA are frequently PET
negative and current guidelines do not endorse PET for iCCA stag-
ing [121]. Regional lymph node metastases are common in iCCA,
and endoscopic ultrasound with ﬁne needle aspirates (FNA) is an
approach to diagnose such metastases [135], but it has not been
rigorously assessed in regards to clinical decision-making and
outcome analysis.
Overview of management of iCCA
Recent guidelines endorse the AJCC/UICCA (7th edition) staging
system [121] and support surgical resection as the treatment of
choice for iCCA, particularly for patients with single intrahepatic
nodules and no dissemination. Conversely, patients with intra-
hepatic metastases, vascular invasion or lymph node metastases
should not undergo resection. There are no established ﬁrst-line
local-regional therapeutic options for patients with non-re-
sectable iCCA, and randomized controlled trials are recommend-
ed. Cisplatin and gemcitabine is a systemic therapy practice
standard for iCCA in patients with ECOG performance status 0
or 1 [136], but the data are too limited to make this an estab-
lished standard of care.
Liver transplantation for iCCA is highly controversial. The
reports on liver transplantation for iCCA are difﬁcult to summa-
rize given the non-standardized selection criteria, small number
of patients, and disparate neoadjuvant and adjuvant treatment
protocols [121]. In most transplant centers, iCCA is considered a
contraindication given the high recurrence rates. However, this
practice has recently been challenged. ‘‘Very early’’ iCCA 62 cm
in diameter in cirrhotic patients may be able to undergo liver
transplantation without recurrence [137]. Further data will be
necessary to support these ﬁndings as well as to clarify if the prog-
nosis of a mixed tumor is worse or not than for HCC [138–141].
In summary, while decades ago liver cancer was a ﬁeld with
grim perspectives and with limited clinical and research activity,
it has evolved into a highly competitive ﬁeld where advance-
ments emerge at a constant rate. Success in preventive approach-
es to eliminate risk factors, better understanding of the molecular
mechanism and reﬁned treatment will further expand the cur-
rent status and ultimately exclude this neoplasm from the top
5 cancer killers.vol. 62 j S144–S156
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